Mammostrat(® )as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

INTRODUCTION: Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, John MS, Thomas, Jeremy, Ross, Douglas T, Seitz, Robert S, Ring, Brian Z, Beck, Rodney A, Pedersen, Hans Christian, Munro, Alison, Kunkler, Ian H, Campbell, Fiona M, Jack, Wilma, Kerr, Gillian R, Johnstone, Laura, Cameron, David A, Chetty, Udi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949634/
https://www.ncbi.nlm.nih.gov/pubmed/20615243
http://dx.doi.org/10.1186/bcr2604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949634/
https://www.ncbi.nlm.nih.gov/pubmed/20615243
http://dx.doi.org/10.1186/bcr2604

Ejemplares similares